Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features

Deborah A. Bowen, Timothy G. Call, Greg D. Jenkins, Clive Z. Zent, Susan M. Schwager, Daniel L. Van Dyke, Diane F Jelinek, Neil Elliot Kay, Tait D. Shanafelt

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

Chronic lymphocytic leukemia (CLL) patients with aggressive molecular characteristics such as deletion of 17p13.1 do not respond to conventional treatments and have a shorter survival. Studies suggest that high-dose methylprednisolone (HDMP) has activity in such patients and combining HDMP with rituximab may enhance efficacy. We identified 37 patients with CLL treated with the HDMP-rituximab who had follow-up at Mayo Clinic. Nine of 27 (33%) had deletion of 17p13.1 and six of 27 (22%) had deletion of 11q22.3. After a median of one cycle of HDMP-rituximab, 29 (78%) patients had an objective response according to the National Cancer Institute CLL Working Group Criteria including five of nine patients with deletion of 17p13.1. Eight (22%) patients had a complete clinical response. Although well tolerated, 11 (29%) patients developed infectious complications before completing one month of therapy. Three-year survival was 41% (95% CI: 26-66%). HDMP-rituximab is an active regimen in patients with relapsed, refractory, and cytogenetically high-risk CLL. Further evaluation of this regimen in controlled trials appears warranted.

Original languageEnglish (US)
Pages (from-to)2412-2417
Number of pages6
JournalLeukemia and Lymphoma
Volume48
Issue number12
DOIs
StatePublished - Dec 2007

Fingerprint

Salvage Therapy
Methylprednisolone
B-Cell Chronic Lymphocytic Leukemia
Cytogenetics
Survival
National Cancer Institute (U.S.)
Rituximab
Therapeutics

Keywords

  • 17P-
  • CLL
  • Methylprednisolone
  • Rituximab
  • Treatment

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. / Bowen, Deborah A.; Call, Timothy G.; Jenkins, Greg D.; Zent, Clive Z.; Schwager, Susan M.; Van Dyke, Daniel L.; Jelinek, Diane F; Kay, Neil Elliot; Shanafelt, Tait D.

In: Leukemia and Lymphoma, Vol. 48, No. 12, 12.2007, p. 2412-2417.

Research output: Contribution to journalArticle

Bowen, Deborah A. ; Call, Timothy G. ; Jenkins, Greg D. ; Zent, Clive Z. ; Schwager, Susan M. ; Van Dyke, Daniel L. ; Jelinek, Diane F ; Kay, Neil Elliot ; Shanafelt, Tait D. / Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. In: Leukemia and Lymphoma. 2007 ; Vol. 48, No. 12. pp. 2412-2417.
@article{fa0bde4a5d044e859499eb44e7c098c1,
title = "Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features",
abstract = "Chronic lymphocytic leukemia (CLL) patients with aggressive molecular characteristics such as deletion of 17p13.1 do not respond to conventional treatments and have a shorter survival. Studies suggest that high-dose methylprednisolone (HDMP) has activity in such patients and combining HDMP with rituximab may enhance efficacy. We identified 37 patients with CLL treated with the HDMP-rituximab who had follow-up at Mayo Clinic. Nine of 27 (33{\%}) had deletion of 17p13.1 and six of 27 (22{\%}) had deletion of 11q22.3. After a median of one cycle of HDMP-rituximab, 29 (78{\%}) patients had an objective response according to the National Cancer Institute CLL Working Group Criteria including five of nine patients with deletion of 17p13.1. Eight (22{\%}) patients had a complete clinical response. Although well tolerated, 11 (29{\%}) patients developed infectious complications before completing one month of therapy. Three-year survival was 41{\%} (95{\%} CI: 26-66{\%}). HDMP-rituximab is an active regimen in patients with relapsed, refractory, and cytogenetically high-risk CLL. Further evaluation of this regimen in controlled trials appears warranted.",
keywords = "17P-, CLL, Methylprednisolone, Rituximab, Treatment",
author = "Bowen, {Deborah A.} and Call, {Timothy G.} and Jenkins, {Greg D.} and Zent, {Clive Z.} and Schwager, {Susan M.} and {Van Dyke}, {Daniel L.} and Jelinek, {Diane F} and Kay, {Neil Elliot} and Shanafelt, {Tait D.}",
year = "2007",
month = "12",
doi = "10.1080/10428190701724801",
language = "English (US)",
volume = "48",
pages = "2412--2417",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "12",

}

TY - JOUR

T1 - Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features

AU - Bowen, Deborah A.

AU - Call, Timothy G.

AU - Jenkins, Greg D.

AU - Zent, Clive Z.

AU - Schwager, Susan M.

AU - Van Dyke, Daniel L.

AU - Jelinek, Diane F

AU - Kay, Neil Elliot

AU - Shanafelt, Tait D.

PY - 2007/12

Y1 - 2007/12

N2 - Chronic lymphocytic leukemia (CLL) patients with aggressive molecular characteristics such as deletion of 17p13.1 do not respond to conventional treatments and have a shorter survival. Studies suggest that high-dose methylprednisolone (HDMP) has activity in such patients and combining HDMP with rituximab may enhance efficacy. We identified 37 patients with CLL treated with the HDMP-rituximab who had follow-up at Mayo Clinic. Nine of 27 (33%) had deletion of 17p13.1 and six of 27 (22%) had deletion of 11q22.3. After a median of one cycle of HDMP-rituximab, 29 (78%) patients had an objective response according to the National Cancer Institute CLL Working Group Criteria including five of nine patients with deletion of 17p13.1. Eight (22%) patients had a complete clinical response. Although well tolerated, 11 (29%) patients developed infectious complications before completing one month of therapy. Three-year survival was 41% (95% CI: 26-66%). HDMP-rituximab is an active regimen in patients with relapsed, refractory, and cytogenetically high-risk CLL. Further evaluation of this regimen in controlled trials appears warranted.

AB - Chronic lymphocytic leukemia (CLL) patients with aggressive molecular characteristics such as deletion of 17p13.1 do not respond to conventional treatments and have a shorter survival. Studies suggest that high-dose methylprednisolone (HDMP) has activity in such patients and combining HDMP with rituximab may enhance efficacy. We identified 37 patients with CLL treated with the HDMP-rituximab who had follow-up at Mayo Clinic. Nine of 27 (33%) had deletion of 17p13.1 and six of 27 (22%) had deletion of 11q22.3. After a median of one cycle of HDMP-rituximab, 29 (78%) patients had an objective response according to the National Cancer Institute CLL Working Group Criteria including five of nine patients with deletion of 17p13.1. Eight (22%) patients had a complete clinical response. Although well tolerated, 11 (29%) patients developed infectious complications before completing one month of therapy. Three-year survival was 41% (95% CI: 26-66%). HDMP-rituximab is an active regimen in patients with relapsed, refractory, and cytogenetically high-risk CLL. Further evaluation of this regimen in controlled trials appears warranted.

KW - 17P-

KW - CLL

KW - Methylprednisolone

KW - Rituximab

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=37149029392&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37149029392&partnerID=8YFLogxK

U2 - 10.1080/10428190701724801

DO - 10.1080/10428190701724801

M3 - Article

VL - 48

SP - 2412

EP - 2417

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 12

ER -